Your browser doesn't support javascript.
loading
Matchmaker Exchange.
Sobreira, Nara L M; Arachchi, Harindra; Buske, Orion J; Chong, Jessica X; Hutton, Ben; Foreman, Julia; Schiettecatte, François; Groza, Tudor; Jacobsen, Julius O B; Haendel, Melissa A; Boycott, Kym M; Hamosh, Ada; Rehm, Heidi L.
Afiliação
  • Sobreira NLM; McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Arachchi H; The Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Buske OJ; Centre for Computational Medicine, Hospital for Sick Children, Toronto, Ontario, Canada.
  • Chong JX; Department of Pediatrics, University of Washington, Seattle, Washington.
  • Hutton B; Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire, United Kingdom.
  • Foreman J; Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridgeshire, United Kingdom.
  • Schiettecatte F; FS Consulting LLC, Seattle, Washington.
  • Groza T; Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.
  • Jacobsen JOB; St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Darlinghurst, New South Wales, Australia.
  • Haendel MA; William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
  • Boycott KM; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon.
  • Hamosh A; Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
  • Rehm HL; McKusick-Nathans Institute of Genetic Medicine (IGM), Clinical Director, IGM. Scientific Director, OMIM. Johns Hopkins University. Baltimore, Maryland.
Curr Protoc Hum Genet ; 95: 9.31.1-9.31.15, 2017 10 18.
Article em En | MEDLINE | ID: mdl-29044468
ABSTRACT
In well over half of the individuals with rare disease who undergo clinical or research next-generation sequencing, the responsible gene cannot be determined. Some reasons for this relatively low yield include unappreciated phenotypic heterogeneity; locus heterogeneity; somatic and germline mosaicism; variants of uncertain functional significance; technically inaccessible areas of the genome; incorrect mode of inheritance investigated; and inadequate communication between clinicians and basic scientists with knowledge of particular genes, proteins, or biological systems. To facilitate such communication and improve the search for patients or model organisms with similar phenotypes and variants in specific candidate genes, we have developed the Matchmaker Exchange (MME). MME was created to establish a federated network connecting databases of genomic and phenotypic data using a common application programming interface (API). To date, seven databases can exchange data using the API (GeneMatcher, PhenomeCentral, DECIPHER, MyGene2, matchbox, Australian Genomics Health Alliance Patient Archive, and Monarch Initiative; the latter included for model organism matching). This article guides usage of the MME for rare disease gene discovery. © 2017 by John Wiley & Sons, Inc.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Predisposição Genética para Doença / Bases de Dados Genéticas / Doenças Raras / Estudos de Associação Genética Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Predisposição Genética para Doença / Bases de Dados Genéticas / Doenças Raras / Estudos de Associação Genética Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article